Exact Mass: 455.22675380000004
Exact Mass Matches: 455.22675380000004
Found 90 metabolites which its exact mass value is equals to given mass value 455.22675380000004,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
20-Hydroxy-leukotriene E4
C23H37NO6S (455.23414620000005)
20-Hydroxy-leukotriene E4 is a metabolite that can originate from the lipid oxidation of leukotriene E4 (LTE4). LTE4 is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4 activates contractile and inflammatory processes via specific interactions with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signaling pathways.
Lacidipine
C26H33NO6 (455.23077580000006)
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Erythroskyrin
C26H33NO6 (455.23077580000006)
Erythroskyrin is a mycotoxin produced by the common food storage mould Penicillium islandicu
Lacidipine
C26H33NO6 (455.23077580000006)
2,6-dimethyl-4-[2-[3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester
C26H33NO6 (455.23077580000006)
Lipoxin E4
C23H37NO6S (455.23414620000005)
3-[11-(3-Hydroxy-5-methyl-hexahydro-furo[3,2-b]furan-2-yl)-undeca-2,4,6,8,10-pentaenoyl]-5-isopropyl-1-methyl-pyrrolidin-2,4-dion|3-[11-(3-hydroxy-5-methyl-hexahydro-furo[3,2-b]furan-2-yl)-undeca-2,4,6,8,10-pentaenoyl]-5-isopropyl-1-methyl-pyrrolidine-2,4-dione
C26H33NO6 (455.23077580000006)
Gly His Arg Ser
Gly His Ser Arg
Gly Pro Pro Trp
C23H29N5O5 (455.21685840000004)
Gly Pro Trp Pro
C23H29N5O5 (455.21685840000004)
Gly Arg His Ser
Gly Arg Ser His
Gly Ser His Arg
Gly Ser Arg His
Gly Trp Pro Pro
C23H29N5O5 (455.21685840000004)
His Gly Arg Ser
His Gly Ser Arg
His Arg Gly Ser
His Arg Ser Gly
His Ser Gly Arg
His Ser Arg Gly
Pro Gly Pro Trp
C23H29N5O5 (455.21685840000004)
Pro Gly Trp Pro
C23H29N5O5 (455.21685840000004)
Pro Pro Gly Trp
C23H29N5O5 (455.21685840000004)
Pro Pro Trp Gly
C23H29N5O5 (455.21685840000004)
Pro Trp Gly Pro
C23H29N5O5 (455.21685840000004)
Pro Trp Pro Gly
C23H29N5O5 (455.21685840000004)
Arg Gly His Ser
Arg Gly Ser His
Arg His Gly Ser
Arg His Ser Gly
Arg Ser Gly His
Arg Ser His Gly
Ser Gly His Arg
Ser Gly Arg His
Ser His Gly Arg
Ser His Arg Gly
Ser Arg Gly His
Ser Arg His Gly
Trp Gly Pro Pro
C23H29N5O5 (455.21685840000004)
Trp Pro Gly Pro
C23H29N5O5 (455.21685840000004)
Trp Pro Pro Gly
C23H29N5O5 (455.21685840000004)
Erythroskyrin
C26H33NO6 (455.23077580000006)
20-hydroxy-LTE4
C23H37NO6S (455.23414620000005)
20-Hydroxy-leukotriene E4
C23H37NO6S (455.23414620000005)
4-[3-[4,7-dimethoxy-6-(2-piperidin-1-ylethoxy)-1-benzofuran-5-yl]-3-hydroxypropyl]phenol
C26H33NO6 (455.23077580000006)
(2R,3R)-N^1^-[(1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl]-N^4^-hydroxy-2-(2-methylpropyl)-3-{[(1,3-thiazol-2-ylcarbonyl)amino]methyl}butanediamide
C20H33N5O5S (455.2202288000001)
Ro 25-6981 maleate
C26H33NO6 (455.23077580000006)
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD)[1][2][3].
ethyl 4-[3-oxo-3-[(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)amino]propanoyl]piperazine-1-carboxylate
C23H29N5O5 (455.21685840000004)
4-[4-[(1R,5S)-3-(1,3-benzodioxol-5-ylmethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
C28H29N3O3 (455.22088040000006)
(3R,6aS,8S,10aS)-3-hydroxy-8-[2-oxo-2-(4-pyrimidinylmethylamino)ethyl]-N-phenyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
C23H29N5O5 (455.21685840000004)
(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N,N-dimethyl-4-[3-[(E)-prop-1-enyl]phenyl]-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
C25H33N3O3S (455.22425080000005)
(3R,6aS,8R,10aS)-3-hydroxy-8-[2-oxo-2-(4-pyrimidinylmethylamino)ethyl]-N-phenyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
C23H29N5O5 (455.21685840000004)
3-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
(3S,6aR,8S,10aR)-3-hydroxy-8-[2-oxo-2-(4-pyrimidinylmethylamino)ethyl]-N-phenyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
C23H29N5O5 (455.21685840000004)
(2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
C28H29N3O3 (455.22088040000006)
3-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
3-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
(3R,6aR,8S,10aR)-3-hydroxy-8-[2-oxo-2-(4-pyrimidinylmethylamino)ethyl]-N-phenyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
C23H29N5O5 (455.21685840000004)
(3S,6aR,8R,10aR)-3-hydroxy-8-[2-oxo-2-(4-pyrimidinylmethylamino)ethyl]-N-phenyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
C23H29N5O5 (455.21685840000004)
(1R,9S,10S,11S)-10-(hydroxymethyl)-6-oxo-5-[(E)-2-phenylethenyl]-N-[(1S)-1-phenylethyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
C28H29N3O3 (455.22088040000006)
(2R,3R,3aS,9bS)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1-methyl-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one
C28H29N3O3 (455.22088040000006)
(2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-N-(4-phenylphenyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C28H29N3O3 (455.22088040000006)
3-[4-[(1S,5R)-6-(1,3-benzodioxol-5-ylmethyl)-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]-N,N-dimethylbenzamide
C28H29N3O3 (455.22088040000006)
diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-3,4-dihydropyridine-3,5-dicarboxylate
C26H33NO6 (455.23077580000006)
[(5E)-5-[2-[4-[2-(dimethylamino)ethoxy]phenyl]-5-(1H-pyridin-4-ylidene)-1H-imidazol-4-ylidene]-2,3-dihydroinden-1-yl]-oxidoazanium
2-Amino-3-[hydroxy-(2-hydroxy-3-tridecanoyloxypropoxy)phosphoryl]oxypropanoic acid
C19H38NO9P (455.2284068000001)
1-tridecanoyl-sn-glycero-3-phosphoserine
C19H38NO9P (455.2284068000001)
CMF019
C25H33N3O3S (455.22425080000005)
CMF019 is a potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents[1]. Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin[2].
Diprotin A (TFA)
Diprotin A TFA (Ile-Pro-Ile TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV)[1].